How do we separate proven findings from marketing hype?
Bone research teaches the sharpest surrogate-endpoint lesson in nutrition: density scans and fracture outcomes are different currencies, regulators require fractures — and the field's most valuable recent findings are what NOT to do (megadose vitamin D boluses, calcium excess, rest-based 'protection'). We interpret the literature in the context of BHOF and Endocrine Society guidelines.
Bone trials reward knowing which endpoint you're being sold:
Julius Wolff formalizes what bone always knew: the skeleton adapts to the loads placed upon it — reinforcing where stress arrives, dismantling where it falls silent.
Fuller Albright identifies postmenopausal bone loss as an estrogen-deficiency state and treats the first patients with estrogen — the beginning of hormonal bone medicine.
Compounds first studied as industrial corrosion inhibitors turn out to be bone-seeking: they embed in mineral and disable osteoclasts. A plumbing chemistry becomes osteoporosis's first-line therapy.
WHO defines osteoporosis by DXA-measured bone density (T-score ≤ −2.5) — the disease becomes measurable before the fracture, and screening becomes possible.
In 36,282 postmenopausal women, combined supplementation produced a modest hip-fracture reduction, clearest in adherent women — the trial that anchors food-and-supplement guidance.
An annual 500,000 IU vitamin D bolus INCREASED falls and fractures versus placebo — the dose-window lesson that reshaped vitamin D guidance toward moderate daily dosing.
Romosozumab and teriparatide rebuild bone rather than slow loss — while campaigns target the real bottleneck: the two-thirds of fragility-fracture patients who still leave the hospital untreated.
POPULATION · 36,282 postmenopausal women
FINDING · Daily calcium (1,000 mg) + vitamin D (400 IU) produced a small hip-fracture reduction overall, statistically clearest in women who actually took the supplements.
LIMITATION · Community-dwelling, largely replete population; adherence dilution; 400 IU of D is below modern tested ranges.
POPULATION · 2,256 community-dwelling women aged 70+, one annual 500,000 IU dose
FINDING · The megadose bolus group suffered MORE falls and MORE fractures than placebo — a dose-window violation, not a deficiency correction.
LIMITATION · Bolus protocol may not generalize to daily dosing; mechanism debated — but the result ended annual-megadose practice.
POPULATION · 101 postmenopausal women with low bone mass, 8 months
FINDING · Supervised heavy resistance training with impact loading improved lumbar spine bone density and functional performance; low-intensity controls declined. No training fractures.
LIMITATION · Small sample, single supervised facility, adherence-dependent — the safety profile belongs to supervised progression, not unsupervised gym improvisation.